SCHEMBL2497359

SCHEMBL2497359

CCC[C@@H](CC(=O)O)c1cccc(O)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRB3 P13945 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
SLC37A4 O43826 1/20 0.36
GABBR2 O75899 1/20 0.35
GABBR1 Q9UBS5 1/20 0.35
CYSLTR2 Q9NS75 1/20 0.35
CYSLTR1 Q9Y271 1/20 0.35
TSHR P16473 1/20 0.34
FFAR1 O14842 1/20 0.34
CTSA P10619 1/20 0.33
BID P55957 3/20 0.33
MCL1 Q07820 3/20 0.33
BCL2L1 Q07817 2/20 0.33
BAK1 Q16611 2/20 0.33
KAT8 Q9H7Z6 2/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2497872 1.00 ADRB1 (0.43) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL3651803 0.88 ADRB1 (0.45) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2499881 0.88 ADRB1 (0.45) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL3658574 0.88 ADRB1 (0.45) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL13882299 0.85 ADRB1 (0.43) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL2497367 0.77 ADRB1 (0.38) ADRB1ADRA2AADRB3ADRA2BADRA2C
SCHEMBL11287832 0.75 CTSA (0.43) GABBR2GABBR1CYSLTR2CYSLTR1CTSA
SCHEMBL9807303 0.75 HPGD (0.54)
SCHEMBL2498695 0.73 ADRA2A (0.43) ADRA2AADRA2BADRA2CCYSLTR2CYSLTR1
SCHEMBL13871772 0.73 CES2 (0.41) CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed